CN111939189A - Application of sparrow mouth tea or extract thereof in preparation of medicine or health-care product for preventing and treating hepatic fibrosis - Google Patents
Application of sparrow mouth tea or extract thereof in preparation of medicine or health-care product for preventing and treating hepatic fibrosis Download PDFInfo
- Publication number
- CN111939189A CN111939189A CN202010853376.2A CN202010853376A CN111939189A CN 111939189 A CN111939189 A CN 111939189A CN 202010853376 A CN202010853376 A CN 202010853376A CN 111939189 A CN111939189 A CN 111939189A
- Authority
- CN
- China
- Prior art keywords
- tea
- liver
- extract
- sparrow
- hepatic fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001122767 Theaceae Species 0.000 title claims abstract description 66
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 33
- 241000287127 Passeridae Species 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 abstract description 18
- 230000002265 prevention Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 36
- 210000004185 liver Anatomy 0.000 description 31
- 102000008186 Collagen Human genes 0.000 description 25
- 108010035532 Collagen Proteins 0.000 description 25
- 229920001436 collagen Polymers 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 208000019425 cirrhosis of liver Diseases 0.000 description 18
- 239000000835 fiber Substances 0.000 description 18
- 239000008096 xylene Substances 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 210000005228 liver tissue Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 14
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 14
- 238000005406 washing Methods 0.000 description 13
- 239000008399 tap water Substances 0.000 description 12
- 235000020679 tap water Nutrition 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 229950000628 silibinin Drugs 0.000 description 7
- 235000014899 silybin Nutrition 0.000 description 7
- 229960004245 silymarin Drugs 0.000 description 7
- 235000017700 silymarin Nutrition 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000013424 sirius red staining Methods 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000012511 Vaccinium Nutrition 0.000 description 3
- 241000736767 Vaccinium Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000007489 histopathology method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 235000013211 Adiantum capillus veneris Nutrition 0.000 description 2
- 241001148501 Adiantum pedatum Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 241000293849 Cordylanthus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000002818 Vaccinium dunalianum Nutrition 0.000 description 2
- 241000733416 Vaccinium dunalianum Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000015911 Amorpha canescens Nutrition 0.000 description 1
- 241000393548 Candidae Species 0.000 description 1
- 244000107780 Capraria biflora Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000013629 Lippia javanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-Butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a sparrow mouth tea or an extract thereof, namely an application of the sparrow mouth tea or the extract thereof in preparing a medicament or a health-care product for preventing or/and treating hepatic fibrosis, belonging to the technical field of natural medicament development or medicines; the experimental result shows that the sparrow tea extract has certain prevention and treatment effects on hepatic fibrosis; the sparrow mouth tea is high in safety, low in price and easy to obtain raw materials; the sparrow tea or the extract thereof has good development and application prospects in the preparation of medicines or health products for preventing and treating hepatic fibrosis diseases.
Description
Technical Field
The invention relates to application of sparrow mouth tea or an extract thereof in preparation of a medicine or a health-care product for preventing or/and treating hepatic fibrosis, and belongs to the technical field of medicines.
Background
Hepatic fibrosis is a common pathological process of various chronic liver diseases and is also a necessary process of cirrhosis and hepatocellular carcinoma. The liver fibrosis is promoted by various factors, such as alcohol intake, virus infection, parasite and chemical toxicity, and the normal structure of the liver is destroyed and the cells are dead after long-term repeated exposure to the pathogenic factors, thereby causing liver dysfunction. The main pathological changes of hepatic fibrosis are hepatocyte degeneration, necrosis with massive inflammatory cell infiltration, unbalanced synthesis and degradation of extracellular matrix (ECM) taking smooth muscle protein (alpha-SMA) and collagen (Col-I) as main components in liver, formation of many fibrous intervals and nodules, change of blood flow in liver and portal hypertension, cause massive pathological and biochemical changes of liver, and finally destroy normal structure and physiological function of liver. The statistical data of Ministry of health shows that the number of chronic hepatitis B virus infected people is up to 3.5 hundred million, wherein China is one of countries with high hepatitis B virus infection rate, infected people reach about 1.2 hundred million people, the detection rate of hepatitis B surface antigen of people is up to 9.75 percent, and the health of people is seriously threatened. With the development of economy and the improvement of the living standard of people, the incidence rate of hepatic fibrosis also presents an obvious rising trend, so that the hepatic fibrosis is always the key and difficult point of research of experts and scholars in the medical field. In recent years, the research on natural plant components with potential protective effect against liver diseases has become a hot spot in the field of food nutrition.
The tea is prepared from Vaccinium camphorata (Vaccinium camphorata) belonging to Vaccinium of EricaceaeVaccinium dunalianum) The flower bud of the plant is named as the cone-shaped like a sparrow mouth. The vaccinium dunalianum is mostly produced in shrubs, India (northeast), Plumbum preparatium, Xijin, Myanmar (northeast), Vietnam, Guizhou, Sichuan, Yunnan, Tibet, Taiwan and the like in China are the main production areas of the vaccinium dunalianum. The sparrow mouth tea is a unique wild tea substitute in Yunnan province, and the tea has the functions of clearing away heat and toxic materials, quenching thirst, refreshing, promoting health, and promoting health,Has the effects of restoring consciousness, softening blood vessels, beautifying and the like, and is a good product for Ming dynasty to pay for. The amino acids in the tea are complete in variety and rich in mineral elements and nutrients, but at present, no literature report is found on the research on the prevention and treatment of hepatic fibrosis diseases by the tea or the extract thereof at home and abroad.
Disclosure of Invention
The invention aims to provide a new application of the sparrow mouth tea and the extract thereof in the aspect of medicine, namely, the sparrow mouth tea or the extract thereof is applied to the preparation of medicines or health-care products for preventing or/and treating hepatic fibrosis.
The medicine or health product for preventing or/and treating hepatic fibrosis takes the extract of the sparrow tea as an active ingredient, is used for preparing the medicine for preventing and treating hepatic fibrosis, can also be added with one or more auxiliary materials acceptable in pharmaceutical preparations, or is compounded with other active ingredients to play a role of synergistically resisting hepatic fibrosis; can be made into pharmaceutically suitable dosage forms or food types.
The preparation of the tea extract of the invention is a conventional method, and the following methods can be adopted but not limited:
ultrasonically extracting herba Zephyranthis Candidae with 60-80% methanol water solution for 20-40min, filtering, repeatedly extracting the residue for 1-2 times, mixing filtrates, concentrating, and lyophilizing.
The invention carries out a series of researches on the prevention and treatment of hepatic fibrosis diseases by the sparrow mouth tea extract, and proves that the sparrow mouth tea extract has the function of preventing and treating hepatic fibrosis, so that the sparrow mouth tea extract can be used for preparing and developing new drugs for preventing and treating hepatic fibrosis. The use of the sparrow tea extract in the preparation of a medicament for preventing and treating liver fibrosis has the following advantages: the tea leaves belong to natural wild, and no artificially synthesized material or antiseptic or pigment agent is added in the production process, so that the safety is high; the extraction and preparation process is simple. At present, there are drugs for liver fibrosis in clinic, but the treatment effect is not obvious and has certain side effects, and if the drugs are used blindly, the burden of the liver is increased, and the recovery of the liver is not facilitated. With the improvement of living standard, the prevalence rate of hepatic fibrosis is gradually increased, so that a novel medicine or health care product with high safety for treating hepatic fibrosis is developed from natural products, and the medicine or health care product has considerable market demand and prospect and has huge social and economic effects.
Compared with the prior art, the invention has the following advantages:
1. the invention explores new medical application of the sparrow mouth tea extract and develops a new research field;
2. experiments show that the sparrow tea extract can effectively relieve liver injury, reduce pathological liver injury and collagen fiber deposition under a lower dosage;
3. the prevention and treatment effect of the tea extract of the bird's beak on hepatic fibrosis is equivalent to that of silymarin (Silibinin), and the tea extract of the bird's beak has simple extraction process and high safety, and is suitable for industrial production and market popularization and application.
Drawings
FIG. 1 is CCl4A picture of induced liver fibrosis mice and sparrow tea extract dry prognosis liver morphology, wherein: control as Control group, CCl4The test result is a model group, Silibinin is a silymarin positive control group, VDEL is a low-concentration Quezui tea group (200 mg/kg), and VDEH is a high-concentration Quezui tea group (600 mg/kg);
FIG. 2 is CCl4Induced liver fibrosis mouse and liver tissue pathological section H of sparrow tea extract dry prognosis&E staining pattern (H)&E×200)；
FIG. 3 is CCl4Masson staining pattern (Masson x 200) of induced liver fibrosis mice and pathological liver histological sections of sparrow tea extract dry prognosis;
FIG. 4 is CCl4Induced liver fibrosis mice and sirius red staining pattern (x 200) of liver histopathological section for sparrow tea extract dry prognosis;
FIG. 5 is a graph of immunohistochemical analysis of α -SMA in liver tissue, wherein: control as Control group, CCl4The test result is a model group, Silibinin is a silymarin positive control group, VDEL is a low-concentration Quezui tea group (200 mg/kg), and VDEH is a high-concentration Quezui tea group (600 mg/kg);
FIG. 6 is a graph of liver immunohistochemistry analysis of alpha-SMA fibrosis factorExpression profile, wherein: # indicates a significant difference from the control group: (p<0.01); (ii) represents significant differences from the model groupp< 0.01）；
FIG. 7 is a photograph of immunohistochemical analysis of Col-I in liver tissue, wherein: control as Control group, CCl4The test result is a model group, Silibinin is a silymarin positive control group, VDEL is a low-concentration Quezui tea group (200 mg/kg), and VDEH is a high-concentration Quezui tea group (600 mg/kg);
FIG. 8 is a photograph of immunohistochemical liver analysis showing expression of Col-I fibrosis factor, wherein: wherein: # indicates a significant difference from the control group: (p<0.01); (ii) represents significant differences from the model groupp< 0.01）。
Detailed Description
The invention is further illustrated below with reference to data from experimental examples and pathological section figures. These experimental examples are only for illustrating the present invention and are not intended to limit the scope of application of the present invention. After reading the description of the present invention, various equivalent changes, modifications and modifications will be apparent to those skilled in the art, which are within the scope of the present invention as defined in the appended claims, and the reagents used in the examples are either conventional commercial products or reagents formulated according to conventional methods, and the methods used in the examples are conventional experimental methods, unless otherwise specified, and histopathological analysis is referred to as "clinical pathology analysis".
Example 1: preparation of extract of Quezui tea
The sparrow mouth tea is collected from Yunan Chuxiong, and is naturally dried and then powdered to obtain a sparrow mouth tea sample; weighing 100g of the maidenhair tea sample, performing ultrasonic-assisted extraction on the sample for 30min by using a methanol aqueous solution with the volume concentration of 70% according to the ratio of g: mL =1:10, filtering, repeatedly extracting filter residues twice, combining filtrates, concentrating and freeze-drying to obtain the maidenhair tea extract.
Example 2: using CCl4The inducing method establishes hepatic fibrosis model, and observes the prevention and treatment effects of the tea extract on hepatic fibrosis by animal model experiment
1. Method for establishing hepatic fibrosis model and experimental process
Male Kunming mouse (21-23 g in weight for 6-8 weeks) was studied with carbon tetrachloride (CCl) at 25% concentration4Peanut oil dilution) to establish a hepatic fibrosis model twice a week for eight weeks; silymarin (Silibinin) is used as a positive control, and the prevention and treatment effect on hepatic fibrosis is evaluated by the Gastringy tea extract; the mice are adapted to groups (8 mice per group) after seven days under a standard environment after being purchased, and are raised according to a conventional raising method, and the specific experimental procedures and groups are as follows:
blank Control (Control) peanut oil was dosed at 5 mL/kg;
model set (CCl)4) 25% CCl given at a dose of 5mL/kg for 8 weeks4Twice a week;
positive control group: gavage 200mg/kg silymarin (Silibinin) at a dose of 5mL/kg for 8 consecutive weeks, wherein 25% CCl was gavaged starting at week 34；
Low concentration que zui tea group (VDEL): gavage 200mg/kg VDE (Quezui tea extract) at 5mL/kg for 8 weeks, wherein gavage 25% CCl starts from week 34
High concentration sparrow tea group (VDEH): gavage 600mg/kg VDE (Quezui tea extract) at 5mL/kg for 8 consecutive weeks, wherein gavage 25% CCl starts from week 34
All animals were fasted (without water) for 12h prior to the first dose; after the experiment is completed, the mouse is anesthetized to be euthanized by chloral hydrate with the mass concentration of 10%, the liver of the mouse is taken out and photographed, part of the liver tissue is taken out and immersed in 10% formalin solution, H & E, Masson and sirius red staining are carried out subsequently, histopathological analysis is carried out, and the expression condition of collagen fibers in the liver tissue is evaluated by observing the change condition of the liver and combining the histopathological analysis of the liver tissue.
The paraffin section preparation method comprises the following steps:
(1) and material taking: fresh liver tissue was fixed with 10% formalin for over 24 h. Taking the liver tissue out of the fixing solution, flattening the tissue of the target part in a fume hood by using a scalpel, and placing the trimmed tissue and the corresponding label in a dehydration box.
(2) And dehydrating and wax dipping: and (5) putting the dehydration box into a dehydration machine for dehydration by gradient alcohol in sequence. The method comprises the following steps of 4 hours of 75% alcohol, 2 hours of 85% alcohol, 2 hours of 90% alcohol, 1 hour of 95% alcohol, 30 minutes of absolute ethyl alcohol I, 30 minutes of absolute ethyl alcohol II, 5-10 minutes of alcohol benzene, 5-10 minutes of xylene I, 5-10 minutes of xylene II, 1 hour of 65-degree melt paraffin I, 1 hour of 65-degree melt paraffin II1h and 1 hour of 65-degree melt paraffin III.
(3) And embedding: embedding the wax-soaked tissue in an embedding machine. Firstly, molten wax is put into an embedding frame, tissues are taken out from a dehydration box and put into the embedding frame according to the requirements of an embedding surface before the wax is solidified, and corresponding labels are attached. Cooling at-20 deg.C, solidifying wax, taking out the wax block from the embedding frame, and trimming the wax block.
(4) And slicing: the trimmed wax block was sliced in a paraffin slicer to a thickness of 4 μm. The slices float on a spreading machine at 40 ℃ warm water to flatten the tissues, a glass slide picks up the tissues, and the slices are baked in a 60 ℃ oven. Baking with water, drying with wax, baking, and storing at room temperature.
HE staining method was as follows:
(1) paraffin section dewaxing to water: sequentially placing the slices into xylene I20 min-xylene II 20 min-absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5min-75% alcohol 5min, and washing with tap water.
(2) And hematoxylin staining: and (3) dyeing the slices in hematoxylin dyeing solution for 3-5min, washing with tap water, differentiating the differentiation solution, washing with tap water, returning blue to the blue solution, and washing with running water.
(3) And eosin staining: the slices are dehydrated for 5min respectively by 85 percent and 95 percent gradient alcohol, and are dyed for 5min in eosin dye solution.
(4) And dehydrating and sealing sheet: placing the slices in anhydrous ethanol I5 min-anhydrous ethanol II 5 min-anhydrous ethanol III 5 min-xylene I5 min-xylene II 5min for transparency, and sealing with neutral gum.
(5) Microscopic examination and image acquisition and analysis.
The Masson staining procedure was as follows:
(1) paraffin section dewaxing to water: sequentially placing the slices into xylene I20 min-xylene II 20 min-absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5min-75% alcohol 5min, and washing with tap water.
(2) The slices were immersed in Masson A solution overnight and washed with tap water.
(3) And slicing into dye liquor mixed by Masson B liquor and Masson C liquor in equal ratio, dip-dyeing for 1min, washing with tap water, differentiating by 1% hydrochloric acid alcohol, and washing with tap water.
(4) The sections were dip-dyed in Masson D for 6 min and rinsed with tap water.
(5) And Masson E solution for dip dyeing for 1 min.
(6) And directly dyeing the fabric for 2-30s by Masson F liquid after slightly draining without washing.
(7) The slices are rinsed and differentiated by 1% glacial acetic acid, and dehydrated by two cylinders of absolute ethyl alcohol.
(8) And transparent sealing sheet: placing the slices in a third jar with anhydrous ethanol for 5min, transparent xylene for 5min, and sealing with neutral gum.
(9) Microscopic examination and image acquisition and analysis.
The sirius red staining method is as follows:
(1) paraffin section dewaxing to water: sequentially placing the slices into xylene I20 min-xylene II 20 min-absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5min-75% alcohol 5min, and washing with tap water.
(2) Sirius red staining: staining the slices in Tianlang scarlet dye liquor for 8min, and dehydrating with two or three vats of anhydrous ethanol;
(3) and dehydrating and sealing sheet: the slices are put into clean xylene for transparency for 5min, and are sealed by neutral gum.
(4) Microscopic examination and image acquisition and analysis.
Immunohistochemical analysis methods were as follows:
(1) paraffin section dewaxing to water: placing the slices in xylene I15 min-xylene II 15 min-xylene III 15 min-absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5min-85% ethyl alcohol 5min-75% ethyl alcohol 5 min-distilled water washing.
(2) And antigen retrieval: placing the tissue slices in a repairing box filled with citric acid antigen repairing buffer solution (pH 6.0) in a microwave oven for antigen repairing, stopping heating for 8min until boiling, maintaining the temperature for 8min, and turning to low and medium heat for 7min to prevent excessive evaporation of the buffer solution. After natural cooling, the slides were washed 3 times for 5min in PBS (pH 7.4) with shaking on a destaining shaker.
(3) Blocking endogenous peroxidase: the sections were placed in 3% hydrogen peroxide solution, incubated for 25 min at room temperature in the dark, and the slides were washed 3 times 5min each time in PBS (pH 7.4) with shaking on a destaining shaker.
(4) And (3) serum blocking, namely dripping 3% BSA (bovine serum albumin) into a grouping ring to uniformly cover the tissues, and blocking for 30min at room temperature.
(5) Adding a primary antibody: gently throwing off the confining liquid, dripping PBS (alpha-SMA and Col-I) prepared according to a certain proportion on the slices, and flatly placing the slices in a wet box for incubation at 4 ℃ overnight.
(6) Adding a secondary antibody: slides were washed 3 times in PBS (pH 7.4) with shaking on a destaining shaker for 5min each time. After the section was slightly spun dry, a secondary antibody (HRP-labeled) to the corresponding species was added dropwise to the ring to cover the tissue, and the mixture was incubated at room temperature for 50 min.
(7) And DAB color development: slides were washed 3 times in PBS (pH 7.4) with shaking on a destaining shaker for 5min each time. After the section is slightly dried, a DAB color developing solution which is prepared freshly is dripped into the ring, the color developing time is controlled under a microscope, the positive color is brown yellow, and the section is washed by tap water to stop color development.
(8) Counterstaining cell nuclei: counter-staining with hematoxylin for about 3min, washing with tap water, differentiating with hematoxylin differentiation solution for several seconds, washing with tap water, returning the hematoxylin to blue, and washing with running water.
(9) And dehydrating and sealing sheet: placing the slices in 75% alcohol for 5min-85% alcohol for 5 min-anhydrous ethanol I for 5 min-anhydrous ethanol II for 5 min-n-butanol for 5 min-xylene I for 5min, dehydrating, removing the slices from xylene, air drying, and sealing with neutral gum.
(10) Microscopic examination and image acquisition and analysis.
The expression of α -SMA and Col-I in immunohistochemistry was quantified using the Image pro6.0 Image analysis system, the mean optical density values were calculated, the mean values were taken after measurement of three sections of the same specimen, the quantification results were expressed as density means (density mean = density and/area sum), and the expression of α -SMA and Col-I was quantified by blank control normalization.
2. Results
2.1 Effect of the extract of Kuckui tea on the histopathological morphology of liver fibrosis mice
After the liver of the mouse is taken out, the fresh isolated liver of the mouse is observed by naked eyes, and the histological examination of the liver is one of the methods for evaluating the liver injury. As shown in FIG. 1, the liver of the mice in the placebo group was reddish brown, smooth in surface, soft in texture, CCl4The liver edges of the mice in the model group are passivated, the surfaces of the mice have a large number of variegated and granular lesions, the texture is hard, the liver of the mice in the 200mg/kg Quezui tea extract group still has local variegated lesions, and the liver shape of the mice in the 600mg/kg Quezui tea extract group is close to that of the blank group.
As shown in fig. 2, after HE staining of liver tissues, in the blank control group, the lobules of mice were intact in structure, and nuclei were clearly visible, and hepatocytes were radially arranged from the central vein to the edges of the lobules without significant necrosis and infiltration of lymphocytes; and CCl4In the model group, the normal structure of the liver lobule of the mouse is damaged, the liver cells in a plurality of small areas are swelled and necrotic, and a large amount of liver cells are swelled and degenerated, inflammatory cells infiltrate and collagen fibers are formed in the damaged area. In the 200mg/kg Quezui tea extract group, the liver lobule damage, inflammatory cell infiltration and cell necrosis of the mice are obviously improved, and in the 600mg/kg Quezui tea extract group, the liver structure of the mice is further improved to be close to the normal structural form, and the effect is better than that of a positive control group; the sparrow tea extract can effectively prevent and treat the occurrence of hepatic fibrosis and has better prevention and treatment effect on the hepatic fibrosis.
2.2 Effect of the extract of Kuckuckthorn on liver fibrosis and fibrosis of mouse liver tissue
Masson staining is a staining method commonly used to show fibrous lesions in tissues, staining makes collagen fibers blue and muscle fibersIt is red. As shown in fig. 3, a clear difference in tissue staining was seen, and in the blank group, the sections were all bright red in color, with no lesions. In CCl4In the model group, obvious fibrosis of tissues is observed, the tissue gaps are enlarged, blue collagen fibers are obviously increased, and the CCl for continuous gavage is shown4Inducing the occurrence of mouse liver fibrosis; in the 200mg/kg que zui tea extract group, the slices were overall reddish and a small amount of collagen fibers could be seen, whereas in the 600mg/kg que zui tea extract group, the slices were overall bright red, closely arranged between tissues and less collagen fibers. And CCl4Compared with a model group, the sparrow tea extract obviously reduces the expression of collagen fibers in the liver of a mouse, and the effect is superior to that of a positive control. It can be seen that the extract of Quezui tea has an obvious improvement effect on hepatic fibrosis.
2.3 Effect of the extract of Kuckuckthorn on the changes of collagen fibers in liver tissues of mice with hepatic fibrosis
The main component of the extracellular matrix is collagen. The mechanism by which tissues are repaired and completed during the repair of body injuries is through the synthesis and degradation of collagen. The collagen fibers are altered throughout the tissue repair process, so understanding the changes in collagen fibers can be understood as the process of wound healing. The general change of collagen can be well expressed by the dyeing of sirius red, the shapes and the distribution of the type I collagen and the type III collagen can be clearly seen in a section, the type I collagen can be clearly seen to show red or yellow under a polarized light mirror, and the type III collagen is green. The experiment further performed sirius red staining on the sections to observe the proliferating collagen fibers in the liver lobules. As shown in fig. 4, it can be clearly seen that there is collagen stained in different colors in the slices, and there is a great difference in the amount of collagen volume. In the blank control group, no obvious collagen fiber deposition was observed; CCl4The model group is of an obvious net structure, and large gaps exist among tissues and are accompanied by a large amount of I-type collagen deposition; the accumulation of collagen fibers in liver tissues of mice is remarkably reduced after different dosages of the tea extract, and the collagen fibers are increased along with the increase of the dosage of the tea extractThe expression is gradually reduced, and the inhibition effect of 600mg/kg of the tea extract on collagen fibers is better than that of a positive control, which shows that the tea extract can effectively inhibit CCl4Induced deposition of liver collagen fibers.
2.4 influence of the extract on the expression of factors related to hepatic fibrosis of liver tissue of mice
alpha-SMA and Col-I are main components constituting ECM, and thus the content of alpha-SMA and Col-I is important index for evaluating liver fibrosis, and the expression level is positively correlated with liver fibrosis degree. Immunohistochemical analysis of mouse liver is shown in FIGS. 5, 6, 7, and 8, comparing CCl with blank control group4The expression levels of alpha-SMA and Col-I in the liver of the mice in the model group are obviously increased (p<0.01), indicating continuous gavage CCl4The occurrence of liver fibrosis in mice is induced. And CCl4Compared with a model group, the 200mg/kg of the sparrow tea extract obviously reduces the expression of alpha-SMA and Col-I in the liver of a mouse (p<0.01), the expression level of the fibrosis-related factors is reduced more remarkably after 600mg/kg of the tea finch extract is given, and the effect is better than that of a positive control.
In summary, the following steps: the extract of herba Caraganae Sinicae is effective in relieving CCl4Induced pathological damage of liver tissues of liver fibrosis mice and deposition of liver collagen fibers, and remarkably reduces the expression of liver fibrosis related factors of the liver tissues of the liver fibrosis mice, thereby determining that the Quezui tea extract can effectively relieve CCl4Induced liver fibrosis of mice, and the effect is better than silymarin (Silibinin).
Claims (2)
1. Application of the sparrow tea or the extract thereof in preparing medicines for preventing or/and treating hepatic fibrosis.
2. The application of the sparrow tea or the extract thereof in preparing health care products for preventing or/and treating hepatic fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010853376.2A CN111939189A (en) | 2020-08-23 | 2020-08-23 | Application of sparrow mouth tea or extract thereof in preparation of medicine or health-care product for preventing and treating hepatic fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010853376.2A CN111939189A (en) | 2020-08-23 | 2020-08-23 | Application of sparrow mouth tea or extract thereof in preparation of medicine or health-care product for preventing and treating hepatic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111939189A true CN111939189A (en) | 2020-11-17 |
Family
ID=73359679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010853376.2A Pending CN111939189A (en) | 2020-08-23 | 2020-08-23 | Application of sparrow mouth tea or extract thereof in preparation of medicine or health-care product for preventing and treating hepatic fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111939189A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524394A (en) * | 2008-10-08 | 2009-09-09 | 云南天秀植物科技开发有限公司 | Quezui tea preparation and application thereof |
| AU2015101749A4 (en) * | 2015-12-03 | 2016-01-14 | Macau University Of Science And Technology | Method of treating or preventing liver injury induced by acetaminophen |
| CN111533770A (en) * | 2020-05-14 | 2020-08-14 | 华侨大学 | Preparation method of arbutin in sparrow tea and application of arbutin in treating hyperuricemia |
-
2020
- 2020-08-23 CN CN202010853376.2A patent/CN111939189A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524394A (en) * | 2008-10-08 | 2009-09-09 | 云南天秀植物科技开发有限公司 | Quezui tea preparation and application thereof |
| AU2015101749A4 (en) * | 2015-12-03 | 2016-01-14 | Macau University Of Science And Technology | Method of treating or preventing liver injury induced by acetaminophen |
| CN111533770A (en) * | 2020-05-14 | 2020-08-14 | 华侨大学 | Preparation method of arbutin in sparrow tea and application of arbutin in treating hyperuricemia |
Non-Patent Citations (1)
| Title |
|---|
| 孙跃: "熊果苷治疗肝纤维化作用及机制", 《中国优秀硕士学位论文全文数据库——医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107167350B (en) | Preparation method of paraffin section of eggplant rhizome tissue | |
| CN106501053B (en) | The paraffin section method of meadowrueleaf corydalis root blade | |
| CN108354956A (en) | Sunflower disk powder and its active ingredient are preparing the application in repairing wounded hepatocytes drug | |
| CN104274601B (en) | A kind of Chinese medicine composition of external curing xerophthalmia and preparation method thereof | |
| US20230057861A1 (en) | Use of corydalis saxicola bunting and formulation thereof in preparation of drug for treating non-alcoholic fatty liver diseases | |
| CN111939189A (en) | Application of sparrow mouth tea or extract thereof in preparation of medicine or health-care product for preventing and treating hepatic fibrosis | |
| CN110448617A (en) | A kind of preparation method and applications of total physalin extract | |
| CN107880113A (en) | A kind of cod collagen peptide and purposes to nonalcoholic fatty liver model with repair | |
| CN107881208A (en) | A kind of preparation method of the cod collagen peptide to nonalcoholic fatty liver model with repair | |
| CN102949472A (en) | Dynamic circulating processing method of prepared radix aconiti and radix aconiti kusnezoffii traditional Chinese medicine decoction piece | |
| CN107213062A (en) | A kind of fair-skinned bright white mildy wash and preparation method thereof | |
| CN116492469A (en) | Application of channel blocker in preparation of medicine for treating and/or preventing liver fiber diseases | |
| WO2023005130A1 (en) | Traditional chinese medicine composition for treating infertility, and preparation method therefor and application thereof | |
| CN110179814A (en) | It a kind of Periostracum cicadae polysaccharide, preparation method and is applied in preparation prevention kidney region fibrosis drug | |
| WO2020248964A1 (en) | Use of rhus chinensis fruit in preparation of drugs for treatment and/or prevention of hepatic fibrosis | |
| CN108192790A (en) | Dendrobium officinale alcohol and preparation method thereof | |
| CN109125206A (en) | A kind of extraction preparation method that dendrobium candidum drips liquid Normal juice and the application in cosmetics | |
| CN114886926A (en) | Turtle shell processing method of Anhydrous tortoise shells | |
| CN114191519A (en) | Application of alpinia japonica alcohol extract in preparation of ultraviolet light aging resistant medicine | |
| CN107519153A (en) | A kind of method that administration by gavage establishes rhesus macaque Liver Fibrosis Model | |
| CN104069156B (en) | A kind of pharmaceutical composition for treating rhinitis and preparation method and application | |
| CN110419492A (en) | It is a kind of to establish the method for building up that oral mucosa fibroid becomes animal model using betelnut extract and mechanical friction | |
| CN111939190A (en) | Application of sparrow mouth tea or extract thereof in preparation of medicine or health product for preventing and treating acute liver injury | |
| CN110179733A (en) | A kind of kiss-me with anti-acne effect skims the cream off milk liquid and preparation method thereof | |
| CN109394632A (en) | A kind of Shu Min moisture retention water and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201117 |
|
| RJ01 | Rejection of invention patent application after publication |